| 摘要 |
A therapeutic combination, useful in the treatment of benign prostatic hyperplasia, includes an inhibitor of 17 beta -hydroxysteroid dehydrogenase activity and at least one further active ingredient selected from the group comprising antiestrogens, inhibitors of 5 alpha -reductase activity and inhibitors of aromatase activity. Pharmaceutical compositions and kits useful for such treatment are also provided. |
